|
2012 Conference Publication Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: A Report from TRANSLATE-ACSHess, Connie N., Wang, Tracy Y., Kaltenbach, Lisa, Honeycutt, Emily, Messenger, John C., Smith, William T., Zettler, Marjorie E., Effron, Mark B., Henry, Timothy D., Peterson, Eric D. and Fonarow, Gregg C. (2012). Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: A Report from TRANSLATE-ACS. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2012 Conference Publication Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity Analysis of the TRIPLET TrialDiodati, Jean, Angiolillo, Dominick, Saucedo, Jorge, Cardillo, Tracy, Jakubowski, Joseph, Henneges, Carsten, Effron, Mark, Lipkin, Fred and Fisher, Harold (2012). Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity Analysis of the TRIPLET Trial. Transcatheter Cardiovascular Therapeutics (TCT) Symposium, Miami Fl, Oct 22-26, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2012.08.764 |
|
2012 Conference Publication TRANSFERRING FROM CLOPIDOGREL LOADING DOSE TO PRASUGREL LOADING DOSE IN ACUTE CORONARY SYNDROME PATIENTS: THE TRIPLET TRIALDiodati, J. G., Fung, A., Saucedo, J. F., Oguzhan, A., Gaxiola, E., Cardillo, T. E., Effron, M. B., Fisher, H. N., Henneges, C. and Angiolillo, D. J. (2012). TRANSFERRING FROM CLOPIDOGREL LOADING DOSE TO PRASUGREL LOADING DOSE IN ACUTE CORONARY SYNDROME PATIENTS: THE TRIPLET TRIAL. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.cjca.2012.07.655 |
|
2012 Conference Publication MEDICATION ADHERENCE AND PERSISTENCE OF PRASUGREL INITIATORS POST ACS-PCISimeone, J. C., Nordstrom, B., Zhao, Z., Molife, C., Mccollam, P. L., Ye, X. and Effron, M. B. (2012). MEDICATION ADHERENCE AND PERSISTENCE OF PRASUGREL INITIATORS POST ACS-PCI. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2012.03.047 |
|
2012 Conference Publication CHARACTERISTICS OF PATIENTS TREATED WITH THIENOPYRIDINES FOLLOWING ACS-PCINordstrom, B., Simeone, J. C., Zhao, Z., Molife, C., Mccollam, P. L., Ye, X. and Effron, M. B. (2012). CHARACTERISTICS OF PATIENTS TREATED WITH THIENOPYRIDINES FOLLOWING ACS-PCI. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2012.03.721 |
|
2012 Conference Publication MEDICATION NONADHERENCE AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDYMathews, Robin, Peterson, Eric, Honeycutt, Emily, Chin, Chee Tang, Ryan, Kelley, Effron, Mark, Zettler, Marjorie, Rozek, Maurice, Henry, Timothy and Wang, Tracy (2012). MEDICATION NONADHERENCE AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY. 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC), Chicago Il, Mar 24-27, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(12)61815-4 |
|
2011 Conference Publication Post-discharge Bleeding and Thienopyridine Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS StudyWang, Tracy Y., Honeycutt, Emily, Henry, Timothy D., Effron, Mark B., Messenger, John C., Cohen, David J., Mark, Daniel B., Stone, Gregg W., Singh, Mandeep, Rozek, Maurice, Fonarow, Gregg C. and Peterson, Eric D. (2011). Post-discharge Bleeding and Thienopyridine Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS Study. 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium, San Francisco Ca, Nov 07-11, 2011. NEW YORK: ELSEVIER SCIENCE INC. |
|
2010 Conference Publication Lack of rebound in platelet reactivity following cessation of prasugrel or clopidogrel in type 2 diabetes mellitus patients with coronary artery disease: insights from OPTIMUS-3Angiolillo, D. J., Jakubowski, J. A., Frelinger, M. U., Zafar, M. U., Saucedo, J. F., Michelson, A. D., Zhu, B., Ojeh, C. K., Baker, B. A. and Effron, M. B. (2010). Lack of rebound in platelet reactivity following cessation of prasugrel or clopidogrel in type 2 diabetes mellitus patients with coronary artery disease: insights from OPTIMUS-3. ESC Congress, Stockholm Sweden, Aug 28-Sep 01, 2010. OXFORD: OXFORD UNIV PRESS. |
|
2009 Conference Publication Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) StudySaucedo, Jorge F., Angiolillo, Dominick J., DeRaad, Roger, Frelinger, Andrew L., Gurbel, Paul A., Costigan, Timothy M., Jakubowski, Joseph A., Ojeh, Clement K. and Effron, Mark B. (2009). Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study. 82nd Scientific Session of the American-Heart-Association, Orlando Fl, Nov 14-18, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2009 Conference Publication Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)Angiolillo, Dominick J., Badimon, Juan, Saucedo, Jorge F., Frelinger, Andrew L., Michelson, Alan D., Jakubowski, Joseph A., Zhu, Baojin, Ojeh, Clement K., Baker, Brian and Effron, Mark B. (2009). Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3). 82nd Scientific Session of the American-Heart-Association, Orlando Fl, Nov 14-18, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2009 Conference Publication PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMESZhu, B., McCollam, P. L., Bae, J. P., Ramaswamy, K., Johnston, J. A. and Effron, M. B. (2009). PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1016/S1098-3015(10)74562-9 |
|
2009 Conference Publication REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIAMahoney, E. M., Wang, K., Bae, J. P., Zhu, B., Marciniak, M. D., Effron, M. B. and Cohen, D. J. (2009). REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1016/S1098-3015(10)74653-2 |
|
2008 Conference Publication COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONSBae, J. P., Zhu, B., McCollam, P. L., Ramaswamy, K., Johnston, J. A., Cohen, D. J. and Effron, M. B. (2008). COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1016/S1098-3015(10)66384-X |
|
2008 Conference Publication Benefit of Facilitated PCI in High Risk ST Elevation MI Patients Presenting to Non-PCI HospitalsHerrmann, Howard C., Liu, Jiandong, Brodie, Bruce R., Armstrong, Paul W., Montalescot, Gilles, Betriu, Amadeo, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S., Topol, Eric. J. and Ellis, Stephen G. (2008). Benefit of Facilitated PCI in High Risk ST Elevation MI Patients Presenting to Non-PCI Hospitals. 20th Annual Transcatheter Cardiovascular Therapeutics Conference, Washington Ca, Oct 12-17, 2008. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. |
|
2008 Conference Publication One year follow up results of the FINESSE trial of facilitated PCIEllis, Stephen G., Tendera, Michael, De Belder, Mark A., van Boven, Ad J., Widimsky, Petr, Janssens, Luc, Andersen, H. R., Betriu, Amadeo, Savonitto, Stefano, Adamus, Jerzy, Peruga, Jan Z., Kosmider, Maciej, Katz, Olivier, Neunteufl, Thomas, Jorgova, Julia, Dorobantu, Maria, Grinfeld, Liliana, Armstrong, Paul, Brodie, Bruce, Herrmann, Howard C., Montalescot, Gilles, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S. and Topol, Eric J. (2008). One year follow up results of the FINESSE trial of facilitated PCI. 57th Annual Scientific Session of the American-College-of-Cardiology, Chicago Il, Mar 29-Apr 01, 2008. NEW YORK: ELSEVIER SCIENCE INC. |
|
2007 Conference Publication The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudyMontalescot, Gilles, Ellis, Stephen G., de Belder, Mark A., Janssens, Luc, Andersen, H. R., Pluta, Wladyslaw, Katz, Olivier, Ecollan, Patrick, Sorensen, Vigholt E., Dawkins, Keith D., Miarka, Jacek, de Belder, Adam, Lederballe, Ole, Adgey, Jennifer, Effron, Mark B. and Barnathan, Elliot S. (2007). The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudy. 19th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington Dc, Oct 20-25, 2007. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. |
|
2007 Conference Publication The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: Results of the formal low molecular weight heparin substudyMontalescot, Gilles, De Belder, Marka A., Janssens, Luc, Andersen, H. R., Pluta, Wladyslaw, Katz, Olivier, Ecollan, Patrick, Sorensen, Vigholt E., Dawkins, Keith D., Miarka, Jacek, De Belder, Adam, Lederballe, Ole, Adgey, Jennifer, Effron, Mark B., Barnathan, Elliot S. and Ellis, Stephen G. (2007). The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: Results of the formal low molecular weight heparin substudy. 19th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington Dc, Oct 20-25, 2007. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. |
|
2005 Conference Publication The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery diseasePatterson, D, Kloner, R, Effron, M, Emmick, J, Bedding, A, Warner, M, Mitchell, M, Braat, S and MacDonald, T (2005). The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Meeting of the International-Society-for-Sexual-and-Impotence-Research, Montreal Canada, Sep, 2002. OXFORD: BLACKWELL PUBLISHING. doi: 10.1111/j.1365-2125.2005.02479.x |
|
2004 Conference Publication Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administrationMann, HJ, Demmon, SL, Boelk, DA, Payne, CA, Effron, MB, Rajagopalan, N, Williams, MD, Beck, GM and Gopalrathnam, G (2004). Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. 38th Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists, New Orleans La, Dec 08-09, 2003. BETHESDA: AMER SOC HEALTH-SYSTEM PHARMACISTS. doi: 10.1093/ajhp/61.24.2664 |
|
2004 Conference Publication Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patientsRickert, T, Jay, S, Michael, C, Karen, S, Pamela, L, Effron, M, Linde-Zwirble, W and Zeckel, M (2004). Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.865S-a |
